Profile - To The Moon

ChaBL

hen r y cha

Posts · 19Posts · 19
Following · 0Following · 0
Followers · 0Followers · 0

- ChaBLChaBL
  ·2021-08-23
  $Apple(AAPL)$go go go
  192 Comment
  1
  Share
  Report
- ChaBLChaBL
  ·2021-06-27
  Up up up
  52 Comment
  1
  Share
  Report
- ChaBLChaBL
  ·2021-06-14
  Good to buy? Comment and like pls?
  69 Comment
  Like
  Share
  Report
- ChaBLChaBL
  ·2021-06-13
  Good counter
  Sorry, this post has been deleted
  176 2
  1
  Share
  Report
- ChaBLChaBL
  ·2021-06-13
  Good counter
  Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares
  Orphazyme A/S says it has no idea why its American depositary shares surged overnight.
  Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares
  136 2
  Like
  Share
  Report
- ChaBLChaBL
  ·2021-06-13
  Go go go
  109 Comment
  Like
  Share
  Report
- ChaBLChaBL
  ·2021-06-01
  Nice
  Nestle, under fire over unhealthy products, working on new strategy
  Nestle said on Monday it was working on updating its nutrition and health strategy after the Financi
  Nestle, under fire over unhealthy products, working on new strategy
  182 Comment
  Like
  Share
  Report
- ChaBLChaBL
  ·2021-06-01
  Buying
  Tech stocks are out of favor — 5 reasons to buy alongside the contrarians
  Life may be returning to normal for most people. But not for die-hard tech stock fans. Their stocks
  Tech stocks are out of favor — 5 reasons to buy alongside the contrarians
  389 Comment
  Like
  Share
  Report
- ChaBLChaBL
  ·2021-06-01
  Nice
  Sorry, this post has been deleted
  360 2
  3
  Share
  Report
- ChaBLChaBL
  ·2021-05-31
  Like and comment pls
  Sorry, this post has been deleted
  277 2
  2
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":3584077823361454,"uuid":"3584077823361454","gmtCreate":1621625238760,"gmtModify":1623547602456,"name":"ChaBL","pinyin":"chabl","introduction":"","introductionEn":null,"signature":"hen r y cha","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":29,"tweetSize":19,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":835524225,"gmtCreate":1629728098867,"gmtModify":1676530114071,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>go go go","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>go go go","text":"$Apple(AAPL)$go go go","images":[{"img":"https://static.tigerbbs.com/66a5125335d4f5bd0ef459258001150e","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835524225","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":124777085,"gmtCreate":1624799253847,"gmtModify":1703845293267,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Up up up","listText":"Up up up","text":"Up up up","images":[{"img":"https://static.tigerbbs.com/7d2d96cae5c1b3ab11788b58c09d2ddc","width":"750","height":"2053"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/124777085","isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":182471763,"gmtCreate":1623601949152,"gmtModify":1704206870860,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good to buy? Comment and like pls?","listText":"Good to buy? Comment and like pls?","text":"Good to buy? Comment and like pls?","images":[{"img":"https://static.tigerbbs.com/e3f26fcb975b4aa8a4b92843bd919912","width":"750","height":"2107"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182471763","isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":186417527,"gmtCreate":1623521299369,"gmtModify":1704205456270,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good counter","listText":"Good counter","text":"Good counter","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/186417527","repostId":"2142202150","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186417164,"gmtCreate":1623521162158,"gmtModify":1704205455458,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good counter&nbsp;","listText":"Good counter&nbsp;","text":"Good counter","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/186417164","repostId":"2142120735","repostType":4,"repost":{"id":"2142120735","pubTimestamp":1623454642,"share":"https://www.laohu8.com/m/news/2142120735?lang=&edition=full","pubTime":"2021-06-12 07:37","market":"other","language":"en","title":"Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2142120735","media":"Bloomberg","summary":"Orphazyme A/S says it has no idea why its American depositary shares surged overnight. ","content":"<p><img src=\"https://static.tigerbbs.com/6ed30e8558b23ac9b494d0aca8d909fc\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> says it has no idea why its American depositary shares surged overnight.</p>\n<p>Danish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly soared almost 1,400% during US trading hours.</p>\n<p>Orphazyme A/S says it has no idea why its American depositary shares surged overnight. When trading started in Copenhagen, the Danish shares rose as much as 76%. The company has now warned investors against being sucked into the frenzy.</p>\n<p>“Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines,” Orphazyme said on Friday morning.</p>\n<p>The only reasonable conclusion to be drawn is that Denmark now has its own meme stock, according to Per Hansen, an investment economist at retail broker Nordnet in Copenhagen. “It’s not just GameStop and AMC that are the subjects of strange, sudden and inexplicable” price developments, Hansen said in a client note.</p>\n<p>“Sometimes, there’s no logical explanation for what happens on the stock market,” he said. “And the development in the share price of Orphazyme is an example of that.” Orphazyme’s ADS soared as much as 1,387% during US hours, before closing about 302% higher.</p>\n<p>Orphazyme said it’s “not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume.”</p>\n<p>Investors in the company have been waiting for an important update on the application of an experimental treatment for Niemann-Pick disease. The drug, called arimoclomol, is under priority review with US authorities, who are due to provide feedback on June 17. But Orphazyme hasn’t provided any recent news on the review that might explain the share move.</p>\n<p>The US Securities and Exchange Commission said this week it’s scrutinizing markets for signs of manipulation as meme stocks continue to surge. That’s as trading in such stocks took off again this week, with chatter building on WallStreetBets and other social media platforms on the potential for short squeezes.</p>\n<p>Orphazyme, which uses heat shock proteins to develop therapies for rare neurodegenerative diseases, has had a turbulent time since its 2017 initial public offering. Shares in the company peaked in February 2020, trading 69% above the IPO price, but are now roughly a third down from the listing, even with Friday’s gains.</p>\n<p>A little more than two hours after trading started in Copenhagen on Friday, shares in Orphazyme were up about 45%, bringing its market value to roughly US$280 million ($370.8 million).</p>\n<p><i>Photo: Bloomberg</i></p>","source":"edge_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 07:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S says it has no idea why its American depositary shares surged overnight.\nDanish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly ...</p>\n\n<a href=\"https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142120735","content_text":"Orphazyme A/S says it has no idea why its American depositary shares surged overnight.\nDanish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly soared almost 1,400% during US trading hours.\nOrphazyme A/S says it has no idea why its American depositary shares surged overnight. When trading started in Copenhagen, the Danish shares rose as much as 76%. The company has now warned investors against being sucked into the frenzy.\n“Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines,” Orphazyme said on Friday morning.\nThe only reasonable conclusion to be drawn is that Denmark now has its own meme stock, according to Per Hansen, an investment economist at retail broker Nordnet in Copenhagen. “It’s not just GameStop and AMC that are the subjects of strange, sudden and inexplicable” price developments, Hansen said in a client note.\n“Sometimes, there’s no logical explanation for what happens on the stock market,” he said. “And the development in the share price of Orphazyme is an example of that.” Orphazyme’s ADS soared as much as 1,387% during US hours, before closing about 302% higher.\nOrphazyme said it’s “not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume.”\nInvestors in the company have been waiting for an important update on the application of an experimental treatment for Niemann-Pick disease. The drug, called arimoclomol, is under priority review with US authorities, who are due to provide feedback on June 17. But Orphazyme hasn’t provided any recent news on the review that might explain the share move.\nThe US Securities and Exchange Commission said this week it’s scrutinizing markets for signs of manipulation as meme stocks continue to surge. That’s as trading in such stocks took off again this week, with chatter building on WallStreetBets and other social media platforms on the potential for short squeezes.\nOrphazyme, which uses heat shock proteins to develop therapies for rare neurodegenerative diseases, has had a turbulent time since its 2017 initial public offering. Shares in the company peaked in February 2020, trading 69% above the IPO price, but are now roughly a third down from the listing, even with Friday’s gains.\nA little more than two hours after trading started in Copenhagen on Friday, shares in Orphazyme were up about 45%, bringing its market value to roughly US$280 million ($370.8 million).\nPhoto: Bloomberg","news_type":1},"isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186414650,"gmtCreate":1623520939370,"gmtModify":1704205454471,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"&nbsp; Go go go","listText":"&nbsp; Go go go","text":"Go go go","images":[{"img":"https://static.tigerbbs.com/259e21758e0b1112530c4f9e78b1e1d4","width":"750","height":"1743"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186414650","isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":110456664,"gmtCreate":1622500106658,"gmtModify":1704185030658,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/110456664","repostId":"1150474590","repostType":4,"repost":{"id":"1150474590","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622454603,"share":"https://www.laohu8.com/m/news/1150474590?lang=&edition=full","pubTime":"2021-05-31 17:50","market":"us","language":"en","title":"Nestle, under fire over unhealthy products, working on new strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1150474590","media":"Reuters","summary":"Nestle said on Monday it was working on updating its nutrition and health strategy after the Financi","content":"<p>Nestle&nbsp;said on Monday it was working on updating its nutrition and health strategy after the Financial Times reported an internal document at the food giant described a large portion of its food and drinks as unhealthy.</p>\n<p>The newspaper said it had seen an internal presentation circulated among top executives early this year stating that more than 60% of Nestle's mainstream food and drinks portfolio could not be considered healthy under a \"recognised definition of health\".</p>\n<p>The paper said this assessment applied to about half of Nestle's overall portfolio because categories like medical nutrition, pet food, coffee and infant formula were excluded from the analysis.</p>\n<p>Kepler Cheuvreux analyst Jon Cox said that including these categories would significantly reduce the proportion of products potentially considered unhealthy.</p>\n<p>\"Given the group’s confectionery, ice cream, and pizza businesses, the real figure for the group based on 2021 estimates would be 28%, which is hardly a surprise,\" he said in a note. He said the report could point to changes in the product portfolio, notably an exit from mainstream confectionary.</p>\n<p>Nestle said in a statement it was working on a \"company-wide project\" to update its nutrition and health strategy and was looking at its entire portfolio to make sure its products helped meet people's nutritional needs.</p>\n<p>It said it had reduced sugars and sodium in its products by about 14-15% in the past seven years and would continue to make its products healthier.</p>\n<p>Nestle shares were 0.2% higher at 0951 GMT, broadly in line with the European food sector.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nestle, under fire over unhealthy products, working on new strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNestle, under fire over unhealthy products, working on new strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-31 17:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nestle&nbsp;said on Monday it was working on updating its nutrition and health strategy after the Financial Times reported an internal document at the food giant described a large portion of its food and drinks as unhealthy.</p>\n<p>The newspaper said it had seen an internal presentation circulated among top executives early this year stating that more than 60% of Nestle's mainstream food and drinks portfolio could not be considered healthy under a \"recognised definition of health\".</p>\n<p>The paper said this assessment applied to about half of Nestle's overall portfolio because categories like medical nutrition, pet food, coffee and infant formula were excluded from the analysis.</p>\n<p>Kepler Cheuvreux analyst Jon Cox said that including these categories would significantly reduce the proportion of products potentially considered unhealthy.</p>\n<p>\"Given the group’s confectionery, ice cream, and pizza businesses, the real figure for the group based on 2021 estimates would be 28%, which is hardly a surprise,\" he said in a note. He said the report could point to changes in the product portfolio, notably an exit from mainstream confectionary.</p>\n<p>Nestle said in a statement it was working on a \"company-wide project\" to update its nutrition and health strategy and was looking at its entire portfolio to make sure its products helped meet people's nutritional needs.</p>\n<p>It said it had reduced sugars and sodium in its products by about 14-15% in the past seven years and would continue to make its products healthier.</p>\n<p>Nestle shares were 0.2% higher at 0951 GMT, broadly in line with the European food sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NSRGY":"雀巢"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150474590","content_text":"Nestle said on Monday it was working on updating its nutrition and health strategy after the Financial Times reported an internal document at the food giant described a large portion of its food and drinks as unhealthy.\nThe newspaper said it had seen an internal presentation circulated among top executives early this year stating that more than 60% of Nestle's mainstream food and drinks portfolio could not be considered healthy under a \"recognised definition of health\".\nThe paper said this assessment applied to about half of Nestle's overall portfolio because categories like medical nutrition, pet food, coffee and infant formula were excluded from the analysis.\nKepler Cheuvreux analyst Jon Cox said that including these categories would significantly reduce the proportion of products potentially considered unhealthy.\n\"Given the group’s confectionery, ice cream, and pizza businesses, the real figure for the group based on 2021 estimates would be 28%, which is hardly a surprise,\" he said in a note. He said the report could point to changes in the product portfolio, notably an exit from mainstream confectionary.\nNestle said in a statement it was working on a \"company-wide project\" to update its nutrition and health strategy and was looking at its entire portfolio to make sure its products helped meet people's nutritional needs.\nIt said it had reduced sugars and sodium in its products by about 14-15% in the past seven years and would continue to make its products healthier.\nNestle shares were 0.2% higher at 0951 GMT, broadly in line with the European food sector.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110458262,"gmtCreate":1622500056356,"gmtModify":1704185029203,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buying&nbsp;","listText":"Buying&nbsp;","text":"Buying","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/110458262","repostId":"1180491418","repostType":4,"repost":{"id":"1180491418","pubTimestamp":1622458949,"share":"https://www.laohu8.com/m/news/1180491418?lang=&edition=full","pubTime":"2021-05-31 19:02","market":"us","language":"en","title":"Tech stocks are out of favor — 5 reasons to buy alongside the contrarians","url":"https://stock-news.laohu8.com/highlight/detail?id=1180491418","media":"MarketWatch","summary":"Life may be returning to normal for most people. But not for die-hard tech stock fans.\nTheir stocks ","content":"<p>Life may be returning to normal for most people. But not for die-hard tech stock fans.</p>\n<p>Their stocks are among the least liked by other investors, according to a&nbsp;recent Bank of America fund manager survey. It found that fund managers have the lowest level allocation toward tech since 2003.</p>\n<p><img src=\"https://static.tigerbbs.com/cfe97072b200641cb5a47b353d9fcdbb\" tg-width=\"1260\" tg-height=\"753\"></p>\n<p>How can this be?</p>\n<p>Tech has a growth issue. That seems odd, but it makes sense if you think it through. Cyclical companies in areas like energy, industry and basic materials caught in the doldrums during the pandemic are now seeing a Phoenix-like reversal of fortune.</p>\n<p>In contrast, sales and earnings at a lot of tech held up OK during the pandemic. So the updraft they get from a rebounding economy looks sort of ho-hum, relatively speaking.</p>\n<p>“Because of COVID, a lot of tech companies saw a lot of growth,” says Vlad Rom, a senior investment analyst at Thrivent, a Minnesota-based money manager. He noted that the pandemic pulled forward tech spending as companies looked for new ways to reach consumers and run meetings.</p>\n<p>“This was not the case for non-tech companies,” he says. Now, as the economy picks up, those non-tech companies are seeing a big growth rebound. “A tech company growing at 30% last year will grow 30% this year. A non-tech company with zero growth last year will grow 50% this year. That is what a lot of investors are focused on.”</p>\n<p>In other words, it’s all about the cyclical trade you’ve been hearing so much about. “The incremental change for a more cyclical business looks better,” says Joseph Chin an analyst at Cambiar Investors in Denver.</p>\n<p>Another problem is that emerging tech companies – think recent initial public offerings – expect their big payoff in profits in the distant future. So they get hit hard when investors fear rapid inflation will send interest rates higher. This reduces the present value of future profits in valuation models.</p>\n<p>In short, tech is out of favor, which makes it a place to shop for contrarians like myself. Indeed, tech has already been putting in a rebound over the past several trading days. The Nasdaq Composite&nbsp;was down 8.5% peak to trough, in its recent pullback. As the S&amp;P 500 index&nbsp;and the Dow Jones Industrial Average&nbsp;flirt with all-time highs, the Nasdaq is still off over 3%.</p>\n<p>“Big tech looks very attractive today especially given the recent underperformance,” says Todd Lowenstein, chief equity strategist at HighMark Capital Management. “It’s a unique opportunity to upgrade your portfolio to quality in big tech, it’s where some of the best value is in the market today.”</p>\n<p>Here are five reasons why.</p>\n<p><b>1. Insiders are buying</b></p>\n<p>For my stock letter (Brush Up on Stocks, link in bio below), I’ve tracked insiders daily for over a decade, and one thing is always clear: Insider buying at tech companies is exceedingly rare. But that’s changed in the past few weeks – which brought an unusually high volume of tech insider buying.</p>\n<p>I just published an issue of my stock letter focusing solely on tech for the first time ever and featured 10 names that look very attractive. I highlighted several others in my letter earlier this month. I single a few out below. Bottom line: The widespread insider interest tells me tech is a buy.</p>\n<p><b>2. Tech’s ‘growth problem’ will go away</b></p>\n<p>The pandemic pulled forward a lot of tech adoption among companies. That makes year-over-year comparisons at tech look challenging as we move through 2021, says Matt Miskin, the co-chief investment strategist at John Hancock Investment Management. ‘But as we go into 2022, we believe the street is underestimating the growth in technology relative to the overall market. We would look opportunistically at tech in the next couple of months.”</p>\n<p><b>3. Tech looks reasonably priced</b></p>\n<p>The chart below shows the relative value of S&amp;P 500 tech stocks compared to the valuation of the S&amp;P 500 itself. As you can see, tech’s price earnings ratio was recently traded at its average 1.24 times the price earnings multiple of the comp.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d5666db47a1ebd117a02d0881dc60e30\" tg-width=\"1260\" tg-height=\"1413\"><span>LEUTHOLD</span></p>\n<p><b>4. Tech has an edge when labor costs are rising</b></p>\n<p>While companies in retail, restaurants, hotels and other service sectors will suffer a hit to margins because of rising labor costs, tech companies typically do not have this problem. They employ relatively fewer people.</p>\n<p>“Perhaps the best way to play the uncertainty surrounding labor costs is technology,” says Leuthold Group chief investment strategist James Paulsen. “Historically, the relative investment performance of this sector has been largely invariant to such pressures.”</p>\n<p><b>5. Interest-rate and inflation fears are overblown</b></p>\n<p>Ironically, tech companies will come to the rescue – and literally save their own stocks. Why? Capital spending rose a lot in the past year. This tells us productivity will continue to increase. That makes it easier for companies to&nbsp;avoid passing higher labor costs on to consumers&nbsp;in the form of price hikes.</p>\n<p>“Long-term growth of this economy is going to have to be driven by productivity growth, and technology will be the key to create that productivity,” says Miskin.</p>\n<p><b>What to buyThe arms dealers in chips</b></p>\n<p>Chip and chip manufacturing companies look underpriced, says Chin at Cambiar Investors, and he singles out Applied Materials.He’s worth listening to because his shop owns the stock in its Cambiar Opportunity Fund.The fund outperforms its large-cap value category and the Russell 1000 Value Index&nbsp;by nearly 5 percentage points annualized over the past three years, says Morningstar.</p>\n<p>Chin cites four reasons to favor Applied Materials: the ongoing chip shortage; the reshoring of chip manufacturing to the U.S.; demand from trends like autonomous vehicles, artificial intelligence and data analytics; and competition among chip makers to improve chip computing power. “We believe Applied Materials and the industry are entering a period of much higher growth,” he says.</p>\n<p>“It will take another four to six quarters for supply to catch up with demand and inventories,” says JP Morgan analyst Harlan Sur, who has an overweight rating on Applied Materials, KLA&nbsp;and Lam Research&nbsp;in chip equipment, and several of the large chip makers including NVIDIA&nbsp;and Microchip Technology.</p>\n<p><b>Names that insiders favor</b></p>\n<p>In the past several weeks I’ve suggested Microsoft,Intel&nbsp;and Snowflake&nbsp;in my stock letter a little below current prices, in part because of the attractive insider buying, and I still like these names.</p>\n<p>Early in big economic rebounds, investors flock to growth, regardless of the quality of companies. But as we move into the mid-cycle, investors favor quality tech names, says Lowenstein, characterized by things like high margins, stable earnings growth and strong balance sheets.</p>\n<p>“If you are screening for quality that is going to lead you to tech,” says Lowenstein.</p>\n<p>This will favor Microsoft in cloud computing and software. Microsoft does not look cheap but the premium valuation is warranted because of its rapid growth, says JP Morgan analyst Mark Murphy.</p>\n<p>Intel shares have been held back by manufacturing issues, but by now the stock looks relatively cheap compared to the market with its price earnings ratio of around 12, says Hendi Susanto a portfolio manager and technology analyst at Gabelli Funds. “Intel is fixing the issue,” says Susanto.</p>\n<p>Intel will also benefit from strong chip demand, and chip shortages. “The industry is only 30%-40% through the current up-cycle,” says Sur, at JP Morgan.</p>\n<p>Snowflake is all about data. That’s its mission. The company offers a product called Data Cloud that helps customers share, explore and unlock the value of data. A big part of the pitch here is that Snowflake helps customers break down data silos inside various pieces of hardware, apps, networks, and clouds. BlackRock and MasterCard agree. They are customers, among dozens of other Fortune 500 companies.</p>\n<p><b>Security software companies</b></p>\n<p>The recent Colonial Pipeline ransomware attack that caused widespread fuel shortages on the East Coast reminded us all of the ongoing need for better security software.</p>\n<p>Gabelli’s Susanto favors firewall company Check Point Software Technologies,citing cheap valuation, high operating margins and prevalence of recurring revenue. Check Point trades at around 22 times earnings compared to more than 60 for security software company Palo Alto Networks.</p>\n<p>RBC Capital Markets analyst Matthew Hedberg has an overweight rating on Palo Alto, citing in part the Colonial Pipeline ransomware attack, as well as the “Sunburst” hack affecting businesses and governments last December, and the Microsoft Exchange Server malware attack in March.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech stocks are out of favor — 5 reasons to buy alongside the contrarians</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech stocks are out of favor — 5 reasons to buy alongside the contrarians\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 19:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/tech-stocks-are-out-of-favor-5-reasons-to-shop-alongside-the-contrarians-11622204518?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Life may be returning to normal for most people. But not for die-hard tech stock fans.\nTheir stocks are among the least liked by other investors, according to a recent Bank of America fund manager ...</p>\n\n<a href=\"https://www.marketwatch.com/story/tech-stocks-are-out-of-favor-5-reasons-to-shop-alongside-the-contrarians-11622204518?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/tech-stocks-are-out-of-favor-5-reasons-to-shop-alongside-the-contrarians-11622204518?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180491418","content_text":"Life may be returning to normal for most people. But not for die-hard tech stock fans.\nTheir stocks are among the least liked by other investors, according to a recent Bank of America fund manager survey. It found that fund managers have the lowest level allocation toward tech since 2003.\n\nHow can this be?\nTech has a growth issue. That seems odd, but it makes sense if you think it through. Cyclical companies in areas like energy, industry and basic materials caught in the doldrums during the pandemic are now seeing a Phoenix-like reversal of fortune.\nIn contrast, sales and earnings at a lot of tech held up OK during the pandemic. So the updraft they get from a rebounding economy looks sort of ho-hum, relatively speaking.\n“Because of COVID, a lot of tech companies saw a lot of growth,” says Vlad Rom, a senior investment analyst at Thrivent, a Minnesota-based money manager. He noted that the pandemic pulled forward tech spending as companies looked for new ways to reach consumers and run meetings.\n“This was not the case for non-tech companies,” he says. Now, as the economy picks up, those non-tech companies are seeing a big growth rebound. “A tech company growing at 30% last year will grow 30% this year. A non-tech company with zero growth last year will grow 50% this year. That is what a lot of investors are focused on.”\nIn other words, it’s all about the cyclical trade you’ve been hearing so much about. “The incremental change for a more cyclical business looks better,” says Joseph Chin an analyst at Cambiar Investors in Denver.\nAnother problem is that emerging tech companies – think recent initial public offerings – expect their big payoff in profits in the distant future. So they get hit hard when investors fear rapid inflation will send interest rates higher. This reduces the present value of future profits in valuation models.\nIn short, tech is out of favor, which makes it a place to shop for contrarians like myself. Indeed, tech has already been putting in a rebound over the past several trading days. The Nasdaq Composite was down 8.5% peak to trough, in its recent pullback. As the S&P 500 index and the Dow Jones Industrial Average flirt with all-time highs, the Nasdaq is still off over 3%.\n“Big tech looks very attractive today especially given the recent underperformance,” says Todd Lowenstein, chief equity strategist at HighMark Capital Management. “It’s a unique opportunity to upgrade your portfolio to quality in big tech, it’s where some of the best value is in the market today.”\nHere are five reasons why.\n1. Insiders are buying\nFor my stock letter (Brush Up on Stocks, link in bio below), I’ve tracked insiders daily for over a decade, and one thing is always clear: Insider buying at tech companies is exceedingly rare. But that’s changed in the past few weeks – which brought an unusually high volume of tech insider buying.\nI just published an issue of my stock letter focusing solely on tech for the first time ever and featured 10 names that look very attractive. I highlighted several others in my letter earlier this month. I single a few out below. Bottom line: The widespread insider interest tells me tech is a buy.\n2. Tech’s ‘growth problem’ will go away\nThe pandemic pulled forward a lot of tech adoption among companies. That makes year-over-year comparisons at tech look challenging as we move through 2021, says Matt Miskin, the co-chief investment strategist at John Hancock Investment Management. ‘But as we go into 2022, we believe the street is underestimating the growth in technology relative to the overall market. We would look opportunistically at tech in the next couple of months.”\n3. Tech looks reasonably priced\nThe chart below shows the relative value of S&P 500 tech stocks compared to the valuation of the S&P 500 itself. As you can see, tech’s price earnings ratio was recently traded at its average 1.24 times the price earnings multiple of the comp.\nLEUTHOLD\n4. Tech has an edge when labor costs are rising\nWhile companies in retail, restaurants, hotels and other service sectors will suffer a hit to margins because of rising labor costs, tech companies typically do not have this problem. They employ relatively fewer people.\n“Perhaps the best way to play the uncertainty surrounding labor costs is technology,” says Leuthold Group chief investment strategist James Paulsen. “Historically, the relative investment performance of this sector has been largely invariant to such pressures.”\n5. Interest-rate and inflation fears are overblown\nIronically, tech companies will come to the rescue – and literally save their own stocks. Why? Capital spending rose a lot in the past year. This tells us productivity will continue to increase. That makes it easier for companies to avoid passing higher labor costs on to consumers in the form of price hikes.\n“Long-term growth of this economy is going to have to be driven by productivity growth, and technology will be the key to create that productivity,” says Miskin.\nWhat to buyThe arms dealers in chips\nChip and chip manufacturing companies look underpriced, says Chin at Cambiar Investors, and he singles out Applied Materials.He’s worth listening to because his shop owns the stock in its Cambiar Opportunity Fund.The fund outperforms its large-cap value category and the Russell 1000 Value Index by nearly 5 percentage points annualized over the past three years, says Morningstar.\nChin cites four reasons to favor Applied Materials: the ongoing chip shortage; the reshoring of chip manufacturing to the U.S.; demand from trends like autonomous vehicles, artificial intelligence and data analytics; and competition among chip makers to improve chip computing power. “We believe Applied Materials and the industry are entering a period of much higher growth,” he says.\n“It will take another four to six quarters for supply to catch up with demand and inventories,” says JP Morgan analyst Harlan Sur, who has an overweight rating on Applied Materials, KLA and Lam Research in chip equipment, and several of the large chip makers including NVIDIA and Microchip Technology.\nNames that insiders favor\nIn the past several weeks I’ve suggested Microsoft,Intel and Snowflake in my stock letter a little below current prices, in part because of the attractive insider buying, and I still like these names.\nEarly in big economic rebounds, investors flock to growth, regardless of the quality of companies. But as we move into the mid-cycle, investors favor quality tech names, says Lowenstein, characterized by things like high margins, stable earnings growth and strong balance sheets.\n“If you are screening for quality that is going to lead you to tech,” says Lowenstein.\nThis will favor Microsoft in cloud computing and software. Microsoft does not look cheap but the premium valuation is warranted because of its rapid growth, says JP Morgan analyst Mark Murphy.\nIntel shares have been held back by manufacturing issues, but by now the stock looks relatively cheap compared to the market with its price earnings ratio of around 12, says Hendi Susanto a portfolio manager and technology analyst at Gabelli Funds. “Intel is fixing the issue,” says Susanto.\nIntel will also benefit from strong chip demand, and chip shortages. “The industry is only 30%-40% through the current up-cycle,” says Sur, at JP Morgan.\nSnowflake is all about data. That’s its mission. The company offers a product called Data Cloud that helps customers share, explore and unlock the value of data. A big part of the pitch here is that Snowflake helps customers break down data silos inside various pieces of hardware, apps, networks, and clouds. BlackRock and MasterCard agree. They are customers, among dozens of other Fortune 500 companies.\nSecurity software companies\nThe recent Colonial Pipeline ransomware attack that caused widespread fuel shortages on the East Coast reminded us all of the ongoing need for better security software.\nGabelli’s Susanto favors firewall company Check Point Software Technologies,citing cheap valuation, high operating margins and prevalence of recurring revenue. Check Point trades at around 22 times earnings compared to more than 60 for security software company Palo Alto Networks.\nRBC Capital Markets analyst Matthew Hedberg has an overweight rating on Palo Alto, citing in part the Colonial Pipeline ransomware attack, as well as the “Sunburst” hack affecting businesses and governments last December, and the Microsoft Exchange Server malware attack in March.","news_type":1},"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110458177,"gmtCreate":1622500013199,"gmtModify":1704185028718,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110458177","repostId":"2139859504","repostType":4,"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110146698,"gmtCreate":1622433994714,"gmtModify":1704184361911,"author":{"id":"3584077823361454","authorId":"3584077823361454","name":"ChaBL","avatar":"https://static.tigerbbs.com/67dfd2a6ef6c84ab706b18238ce78468","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110146698","repostId":"2139979480","repostType":4,"isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}